All In MedTech

Device Trial Radar · NCT05565443

MR-guided Focused Ultrasound Plus GCase

A Phase I/II Study for Bilateral Putamenal Delivery of Recombinant Glucocerebrosidase in Patients With Parkinson's Disease Using MR-guided Focused Ultrasound Induced Opening of the Blood-brain Barrier

Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

14

Planned (sponsor's estimate)

Start

Nov 30, 2022

Primary completion

Nov 1, 2026

Study completion Dec 31, 2028

Sponsor

Lead sponsor
InSightecNot on our public-company list
Sponsor type
Industry
First posted
Oct 4, 2022

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 35 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this study is to establish safety and feasibility of intracerebral delivery of GCase via MRgFUS. This technique may offer potential benefits given the exposure of the putamen to GCase in animal models has been shown to be efficacious in improving Parkinson's disease pathology and phenotype.

Conditions

  • Parkinsons Disease

Interventions

  • Blood Brain Barrier Disruption - FunctionalDevice

    Delivery of GCase across the BBB to form a disease modifying strategy for patients with Parkinson's Disease

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse EventsTime frame: 12 Months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Sunybrook Research Institute

    Toronto, Ontario, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.